Navigation Links
AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
Date:5/22/2008

WILMINGTON, Del., May 22 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it supports the revised Physician Payment Sunshine Act as part of the company's latest step to provide the public with more information about the way it does business.

Sponsored by Sens. Charles Grassley of Iowa and Herb Kohl of Wisconsin, the legislation would create a national registry of payments that biopharmaceutical companies, device manufacturers and medical supply companies make to medical organizations and health care providers.

"AstraZeneca believes that providing information to the public about our company, our products and how we do business is integral to improving patient health," said Tony Zook, President and CEO, AstraZeneca Pharmaceuticals, LP, U.S. "We are pleased to support this legislation that will create greater transparency around our relationships with physicians, while helping the public understand how we work with health care providers."

Zook praised Sens. Grassley and Kohl for their leadership on the legislation -- and especially for creating a single uniform registry that would capture payments made to physicians by biopharmaceutical companies, device manufacturers and medical supply companies. "This is the best approach to provide physician payment information to patients," Zook said.

AstraZeneca is proud that it improves patient health by helping ensure physicians are knowledgeable about our products and patient assistance programs, and by providing physicians with timely, relevant information that enables them to make the best treatment decisions for their patients.

In supporting the Physician Payment Sunshine Act, AstraZeneca builds on the transparency initiative it launched in March. AstraZeneca previously announced it will publicly share additional or enhanced information about its policy positions, political contributions, medical education grants, contributions to nonprofit organizations, and post-marketing study commitments, as well as making information on its compliance program and clinical trials more visible on its Web site.

Beginning at various stages this year, elements of the company's previously announced transparency initiative will be available at AstraZeneca's U.S. Web site http://www.astrazeneca-us.com, in an effort to better inform the public about how the company conducts its business and how it is helping patients through research and support for external organizations.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit http://www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
8. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
9. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
10. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
11. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
(Date:6/22/2016)... Research and Markets has announced the addition of the "Biomarkers: ... The global biomarkers market has grown ... market is expected to grow at a five-year compound annual growth ... billion in 2015 to $96.6 billion in 2020. ... 2020) are discussed. As well, new products approved in 2013 and ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):